XML 47 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
BUSINESS ACQUISITIONS AND DIVESTITURE - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 04, 2018
Oct. 02, 2017
May 25, 2017
Feb. 24, 2017
Aug. 31, 2017
Mar. 31, 2018
Dec. 31, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2017
Oct. 06, 2017
Business Acquisition [Line Items]                      
Amount drawn from loan           $ 25,000,000     $ 210,000,000    
Cash received from working capital adjustment related to business acquisition           5,700,000          
Payment for contingent consideration           7,800,000          
Realized loss on sale of short-term investment               $ 2,300,000      
Change in fair value of contingent consideration           379,000     261,000    
Net income           10,992,000     $ 6,394,000    
Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition                      
Business Acquisition [Line Items]                      
Net income           $ 9,000,000          
Product Concentration Risk | BioD Morselized Amniotic Membrane Based Products                      
Business Acquisition [Line Items]                      
Percentage of revenue to product (less than)           1.00%     1.00%    
Derma Sciences | Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition                      
Business Acquisition [Line Items]                      
Net income           $ 2,900,000          
Codman Specialty Surgical                      
Business Acquisition [Line Items]                      
Aggregate purchase price received                     $ 46,400,000
Assets provided upon termination of transitional supply agreement liability             $ 1,300,000     $ 1,300,000  
Disposal Group, Held-for-sale, Not Discontinued Operations | Codman Specialty Surgical                      
Business Acquisition [Line Items]                      
Pretax gain on sale of business, included in other income, net                   2,600,000  
Subsequent Event                      
Business Acquisition [Line Items]                      
Cash received from working capital adjustment related to business acquisition $ 21,000,000                    
Codman                      
Business Acquisition [Line Items]                      
Consideration for acquisition   $ 1,014,000,000                  
Revenue of acquired company           77,900,000          
Purchase price adjustments           2,783,000          
Purchase price, working capital adjustments           5,700,000          
Purchase price, inventory adjustments           2,900,000          
Write off of construction in progress             6,300,000        
Codman | Secured Debt | Term Loan A-1                      
Business Acquisition [Line Items]                      
Amount drawn from loan   $ 700,000,000                  
Derma Sciences                      
Business Acquisition [Line Items]                      
Consideration for acquisition       $ 210,800,000              
Revenue of acquired company           24,700,000     $ 10,400,000    
Payment of closing expenses       4,800,000              
Settlement of stock compensation plan       4,300,000              
Cash payment to former shareholders       201,700,000              
Acquired deferred taxes       $ 14,524,000   14,500,000          
Deferred tax asset, federal net operating loss           39,700,000          
Deferred tax asset, intangibles           16,400,000          
Deferred tax liabilities, intangibles           41,100,000          
Deferred tax asset, various           500,000          
Deferred tax liabilities, adjustment to estimated fair value               1,500,000      
Deferred tax assets, adjustment to estimated fair value             3,300,000     3,300,000  
Derma Sciences | BioD Earnout Payments                      
Business Acquisition [Line Items]                      
Payment for contingent consideration         $ 4,800,000            
Revenue volatility percentage       13.50%              
Fair value inputs, discount rate       3.00%              
Contingent consideration maximum payout       $ 26,500,000              
Estimated fair value of the remaining portion of the contingent consideration, liability       $ 9,100,000   300,000 300,000     300,000  
Derma Sciences | Product Payment Contingent Consideration                      
Business Acquisition [Line Items]                      
Fair value inputs, discount rate       2.50%              
Contingent consideration maximum payout       $ 29,700,000.0              
Estimated fair value of the remaining portion of the contingent consideration, liability       $ 26,800,000              
Product payment rate       98.00%              
Change in fair value of contingent consideration               $ 900,000      
Payment for the product payment     $ 26,600,000                
Derma Sciences | Medihoney Earnout Payments                      
Business Acquisition [Line Items]                      
Revenue volatility percentage       27.50%              
Fair value inputs, discount rate       4.50%              
Contingent consideration maximum payout       $ 5,000,000.0              
Estimated fair value of the remaining portion of the contingent consideration, liability       $ 1,400,000   $ 1,400,000 $ 1,400,000     $ 1,400,000